Onset of effects of testosterone treatment and time span until maximum effects are achieved
Open accessAbstract
Objective: Testosterone has a spectrum of effects on the male organism. This review attempts to determine, from published studies, the time-course of the effects induced by testosterone replacement therapy from their first manifestation until maximum effects are attained. Design: Literature data on testosterone replacement. Results: Effects on sexual interest appear after 3 weeks plateauing at 6 weeks, with no further increments expected beyond. Changes in erections/ejaculations may require up to 6 months. Effects on quality of life manifest within 3–4 weeks, but maximum benefits take longer. Effects on depressive mood become detectable after 3–6 weeks with a maximum after 18–30 weeks. Effects on erythropoiesis are evident at 3 months, peaking at 9–12 months. Prostate-specific antigen and volume rise, marginally, plateauing at 12 months; further increase should be related to aging rather than therapy. Effects on lipids appear after 4 weeks, maximal after 6–12 months. Insulin sensitivity may improve within few days, but effects on glycemic control become evident only after 3–12 months. Changes in fat mass, lean body mass, and muscle strength occur within 12–16 weeks, stabilize at 6–12 months, but can marginally continue over years. Effects on inflammation occur within 3–12 weeks. Effects on bone are detectable already after 6 months while continuing at least for 3 years. Conclusion: The time-course of the spectrum of effects of testosterone shows considerable variation, probably related to pharmacodynamics of the testosterone preparation. Genomic and non-genomic effects, androgen receptor polymorphism and intracellular steroid metabolism further contribute to such diversity.
AI snapshot
Written from the paper’s full text.
TL;DR
This review charts the published time-course of testosterone replacement effects in hypogonadal men, from first manifestation to maximum effect. It finds considerable variation across outcomes, probably related to testosterone preparation pharmacodynamics, genomic and non-genomic effects, androgen receptor polymorphism, and intracellular steroid metabolism.
Key findings
- Sexual interest/libido appears after 3 weeks and plateaus at 6 weeks; erections/ejaculations may require up to 6 months; depressive mood becomes detectable after 3–6 weeks with a maximum after 18–30 weeks.
- Erythropoiesis is evident at 3 months and peaks at 9–12 months; PSA and prostate volume rise marginally and plateau at 12 months; lipid effects appear after 4 weeks and are maximal after 6–12 months.
- Insulin sensitivity may improve within days, but glycemic control effects become evident only after 3–12 months; fat mass, lean body mass, and muscle strength change within 12–16 weeks, stabilize at 6–12 months, and can marginally continue over years; bone effects are detectable after 6 months and continue at least 3 years.
- Effects on inflammation occur within 3–12 weeks.
Methods
- Literature review of testosterone replacement data, searching MEDLINE, the Cochrane Library, EMBASE, and Current Contents for 1976–2011, plus bibliographies and references of retrieved/review articles.
- Inclusion criteria: one active treatment group compared with matched placebo/control, description of the time-course of active treatment, randomization, protocol adherence, and single/double blinding; only peer-reviewed medical journal articles, no abstracts.
- Main analysis: qualitative synthesis of onset and maximum-effect time points across target systems, summarized in figures.
Limitations
- The paper states that almost none of the quoted studies were specifically designed to assess the time-course of effects; some studies measured effects only after 3 months, particularly missing earlier libido and erection effects.
- The paper states that sub-optimal therapeutic regimens or inappropriate patient selection (eugonadal men or men with biochemical but not clinical hypogonadism) may show a different time-course, and the analysis was restricted to testosterone treatment, excluding androgen deprivation therapy.
- Evident from the text: as a narrative review without meta-analysis, time-course estimates depend on heterogeneous studies, preparations, doses, and follow-up schedules, and no formal quantitative pooling or risk-of-bias assessment is reported.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
0 of 183 cited sources checked · 0 supported · 0 flagged
- Findingcitation
Changes in erections and ejaculations may require up to 6 months.
“Changes in erections/ejaculations may require up to 6 months.”
- Also stated in: § Effects on erection/ejaculation · hedged
“Maximal effects are usually achieved after 3–6 months (72) but may take even up to 1 year in individual cases (71).”
Quote in the paperSubstantial claim0 of 2 sources checked - Also stated in: § Effects on erection/ejaculation · hedged
- Findingcitation
Effects of testosterone on glycemic control become evident only after 3-12 months.
“Insulin sensitivity may improve within few days, but effects on glycemic control become evident only after 3–12 months.”
Quote in the paperSubstantial claim0 of 3 sources checked - Findingcitation
Insulin sensitivity may improve within a few days of testosterone administration.
“Insulin sensitivity may improve within few days, but effects on glycemic control become evident only after 3–12 months.”
- Also stated in: § Time-course of effects on glycemic control · boosted
“And indeed, in an experimental study, stimulation of endogenous testosterone was shown to increase insulin sensitivity within 48 h (49).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [49] source
Not checked in the free run.
- Also stated in: § Time-course of effects on glycemic control · boosted
- Findingcitation
Effects of testosterone on inflammation occur within 3-12 weeks.
“Effects on inflammation occur within 3–12 weeks.”
Quote in the paperSubstantial claim0 of 3 sources checked - Findingcitation
Changes in fat mass, lean body mass, and muscle strength occur within 12-16 weeks of testosterone treatment.
“Changes in fat mass, lean body mass, and muscle strength occur within 12–16 weeks, stabilize at 6–12 months, but can marginally continue over years.”
Quote in the paperSubstantial claim0 of 3 sources checked
- Findingcitation
Changes in fat mass, lean body mass, and muscle strength stabilize at 6-12 months of testosterone treatment.
“Changes in fat mass, lean body mass, and muscle strength occur within 12–16 weeks, stabilize at 6–12 months, but can marginally continue over years.”
Quote in the paperSubstantial claim0 of 3 sources checked - Findingreasoning
The time-course of the spectrum of effects of testosterone shows considerable variation.
“The time-course of the spectrum of effects of testosterone shows considerable variation, probably related to pharmacodynamics of the testosterone preparation.”
- Also stated in: § Discussion · plain
“We noticed considerable differences in the occurrence of effects of testosterone.”
Quote in the paperSubstantial claim - Also stated in: § Discussion · plain
- Findingcitation
Changes in fat mass, lean body mass, and muscle strength can marginally continue over years of testosterone treatment.
“Changes in fat mass, lean body mass, and muscle strength occur within 12–16 weeks, stabilize at 6–12 months, but can marginally continue over years.”
Quote in the paperSubstantial claim0 of 2 sources checked - Findingcitation
The decrease in serum total cholesterol reaches a maximum after 12 months of testosterone treatment.
“others have found this to occur after 9 months (41) or 12 months (42) with a maximum reached after 12 months (32).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [32] source
Not checked in the free run.
- Findingcitation
Serum glucose is reduced after 3 months of testosterone administration in men with impaired glucose tolerance.
“Several studies indicate that upon testosterone administration, serum glucose is reduced after 3 months in men with impaired glucose tolerance (31, 36, 43).”
Quote in the paperSubstantial claim0 of 3 sources checked - Findingcitation
An improvement in insulin sensitivity upon testosterone administration results in reduced fasting glucose and insulin levels within a single week.
“An improvement in insulin sensitivity upon testosterone administration resulted in reduced fasting glucose and insulin levels within a single week (50)”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [50] source
Not checked in the free run.
- Findingcitation
Concomitantly increasing testosterone and decreasing estradiol levels has positive effects on postprandial triglyceride handling and insulin sensitivity.
“Concomitantly increasing testosterone and decreasing estradiol (E2) levels had positive effects on both postprandial triglyceride handling and insulin sensitivity in elaborate clamp models during manipulation of these serum sex steroid levels (50).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [50] source
Not checked in the free run.
- Findingcitation
In men with coronary artery disease, flow-mediated vasodilatation is observed after 12 weeks of testosterone treatment.
“In men with coronary artery disease flow-mediated vasodilatation was observed after 12 weeks (61).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [61] source
Not checked in the free run.
- Findingcitation
In patients with Crohn's disease, C-reactive protein levels continue to decline over 24 months of testosterone treatment.
“In a study in patients with Crohn's disease, CRP levels continued to decline over 24 months (65).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [65] source
Not checked in the free run.
- Findingcitation
Resting heart rate decreases after 40-44 weeks of testosterone treatment.
“A decrease in the resting heart rate occurred after 40–44 weeks (44).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [44] source
Not checked in the free run.
- Findingcitation
Maximum blood pressure effects of testosterone treatment are observed after 12 months.
“Maximum effects were observed after 12 months (35).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [35] source
Not checked in the free run.
- Findingcitation
In men with chronic stable angina pectoris, the increase in time to 1 mm ST segment depression is noticeable after 14 weeks of testosterone treatment.
“In men with chronic stable angina pectoris the increase in time to 1 mm ST segment depression was noticeable after 14 weeks (59).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [59] source
Not checked in the free run.
- Findingcitation
Testosterone administration increases the response of postprandial glucose-dependent insulinotropic polypeptide (GIP) release.
“Furthermore, the aforementioned intervention increased the response of postprandial glucose-dependent insulinotropic polypeptide (GIP) release (50).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [50] source
Not checked in the free run.
- Findingcitation
Testosterone administration decreases tumor necrosis factor α and interleukin 1β after 4 weeks.
“A decrease in tumor necrosis factor α and in interleukin 1β was noted after 4 weeks (39).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [39] source
Not checked in the free run.
- Findingcitation
In patients with veno-occlusive dysfunction, testosterone undecanoate restores erectile function after a minimum of 3 months and a maximum of 11.5 months.
“In patients with veno-occlusive dysfunction, testosterone undecanoate restored erectile function after a minimum of 3 months and a maximum of 11.5 months (71).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [71] source
Not checked in the free run.
- Findingcitation
Effects of testosterone on libido, sexual desire, sexual thoughts and fantasies, and satisfaction with sexual life manifest after 3 weeks or 30 days.
“Effects on libido, sexual desire, sexual thoughts and fantasies and satisfaction with sexual life manifest themselves rather rapidly: after 3 weeks (68) or 30 days (14).”
Quote in the paperSubstantial claim0 of 2 sources checked - Findingcitation
Effects of testosterone on erection appear after 3 weeks.
“Effects on erection also appear rather rapidly: after 3 weeks (68).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [68] source
Not checked in the free run.
- Findingcitation
Morning erections increase after 3 weeks of testosterone treatment.
“Increase in morning erections occur after 3 weeks (68).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [68] source
Not checked in the free run.
- Findingcitation
Decrease in fatigue and listlessness occurs after 1 month or 6 weeks of testosterone treatment.
“A decrease in fatigue and listlessness was found after 1 month (31) or 6 weeks (68).”
Quote in the paperSubstantial claim0 of 2 sources checked - Findingcitation
Improvement in depression is reported after 3 weeks or 1 month of testosterone treatment.
“Several studies report an improvement in depression after 3 weeks (68) or 1 month (38).”
Quote in the paperSubstantial claim0 of 2 sources checked - Findingcitation
Improvement in depression on the Hamilton Depression Rating Scale occurs after 6 weeks or 8 weeks of testosterone treatment.
“Two studies using the Hamilton Depression Rating Scale found an improvement in depression after 6 weeks (75) or 8 weeks (76).”
Quote in the paperSubstantial claim0 of 2 sources checked- cites [75]
Not checked in the free run.
- cites [76] source
Not checked in the free run.
- Findingcitation
An improvement on the ADAM score is noted after 1 month of testosterone treatment.
“An improvement was noted after 1 month of testosterone treatment (38).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [38] source
Not checked in the free run.
- Findingcitation
A transient increase in anger/hostility occurs in eugonadal men whose testosterone levels are raised above normal after 2 weeks.
“A transient increase in anger/hostility was found in eugonadal men whose testosterone levels were raised above normal after 2 weeks (77).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [77] source
Not checked in the free run.
- Findingcitation
Higher age is a factor in the effects of testosterone on red blood cell formation.
“The effects of testosterone on red blood cell formation (hemoglobin and hematocrit) are dose dependent (14, 82, 83) while higher age is also a factor (44).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [44] source
Not checked in the free run.
- Findingcitation
In hypogonadal men treated with testosterone, prostate-specific antigen levels rise usually up to levels of eugonadal men.
“In hypogonadal men treated with testosterone, levels of PSA rise usually up to levels of eugonadal men (84).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [84] source
Not checked in the free run.
- Findingcitation
Effects of testosterone on red blood cell formation (hemoglobin and hematocrit) are dose dependent.
“The effects of testosterone on red blood cell formation (hemoglobin and hematocrit) are dose dependent (14, 82, 83) while higher age is also a factor (44).”
Quote in the paperNot a substantial claim0 of 3 sources checked - Findingcitation
Effects of testosterone administration on the ability to process spatial data of visual content are observed within 2 weeks of treatment.
“Similarly, effects of testosterone administration in hypogonadal men on the ability to process spatial data of visual content were observed within 2 weeks of treatment (80).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [80] source
Not checked in the free run.
- Findingcitation
Effects of testosterone on depressive symptoms are more pronounced in men with the lowest baseline testosterone levels.
“It is remarkable that effects were more pronounced in men with the lowest baseline testosterone levels (79).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [79] source
Not checked in the free run.
- Findingreasoning
Effects of testosterone on glycemic control and variables clustered in the metabolic syndrome occur somewhat slower.
“The effects of testosterone on glycemic control and variables clustered in the metabolic syndrome occur somewhat slower”
Quote in the paperSubstantial claim - Findingnone given
One study over 24 months found no significant increase in both prostate-specific antigen and prostate volume.
“One study over 24 months found no significant increase in both PSA and prostate volume.”
Quote in the paperNot a substantial claim - Findingcitation
In a study of 81 hypogonadal men followed for a mean of 33.8 months, prostate-specific antigen levels did not increase significantly at 1-year intervals for 5 years.
“In a study of 81 hypogonadal men (mean age 56.8 years) followed for a mean (range) of 33.8 (6–144) months PSA levels did not increase significantly at 1-year intervals for 5 years (88).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [88] source
Not checked in the free run.
- Interpretationcitation
Further increase in prostate-specific antigen or prostate volume beyond 12 months of testosterone therapy should be related to aging rather than therapy.
“further increase should be related to aging rather than therapy.”
- Also stated in: § Time-course of effects on the prostate · plain
“Upon judging the time-course of effects of testosterone on the prostate, it is of note that aging itself is a factor in the rise of both prostate volume and PSA (84), and there is no endpoint in the effects of testosterone on the prostate.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [84] source
Not checked in the free run.
- Also stated in: § Time-course of effects on the prostate · plain
- Premisecitation
If the dose of testosterone administered is too low, no effects may be demonstrable.
“If the dose administered is too low, no effects may be demonstrable (10).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [10] source
Not checked in the free run.
- Premisecitation
Testosterone administration for 20 weeks is associated with dose-dependent increases in skeletal muscle mass, leg strength, and power.
“Testosterone administration for 20 weeks was associated with dose-dependent increases in skeletal muscle mass, leg strength, and power (13).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [13] source
Not checked in the free run.
- Interpretationcitation
Genomic and non-genomic effects, androgen receptor polymorphism, and intracellular steroid metabolism further contribute to the diversity of the time-course of testosterone effects.
“Genomic and non-genomic effects, androgen receptor polymorphism and intracellular steroid metabolism further contribute to such diversity.”
Quote in the paperSubstantial claim0 of 2 sources checked - Interpretationreasoning
The variation in the time-course of testosterone effects is probably related to the pharmacodynamics of the testosterone preparation.
“The time-course of the spectrum of effects of testosterone shows considerable variation, probably related to pharmacodynamics of the testosterone preparation.”
Quote in the paperSubstantial claim - Premisecitation
High doses of testosterone gel (starting dose 100 mg/day with possible up-titration to 150 mg/day) produce significant increases in leg press strength, chest press strength, and stair climbing power within 6 months.
“Another study using high doses of testosterone gel (starting dose 100 mg/day with possible up-titration to 150 mg/day) observed significant increases in leg press strength, chest press strength, and stair climbing power with a load within 6 months (16).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [16] source
Not checked in the free run.
- Premisecitation
Testosterone produces a consistent reduction in bone resorption markers.
“Testosterone produces a consistent reduction in bone resorption markers (20).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [20] source
Not checked in the free run.
- Premisecitation
Effects of testosterone on bone mineral density have been shown in studies of 6 months, 8 months, or 1 year duration.
“Effects on bone mineral density have been shown in studies of 6 months duration (21, 22), 8 months duration (23), or 1 year duration (24).”
Quote in the paperSubstantial claim0 of 3 sources checked - Premisecitation
Stimulation of endogenous testosterone increases insulin sensitivity within 48 h.
“And indeed, in an experimental study, stimulation of endogenous testosterone was shown to increase insulin sensitivity within 48 h (49).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [49] source
Not checked in the free run.
- Premisecitation
Low serum testosterone levels are associated with an adverse metabolic profile.
“Low serum testosterone levels are associated with an adverse metabolic profile which may be explained by the observation that low testosterone levels and impaired mitochondrial function promote insulin resistance in men (48).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [48] source
Not checked in the free run.
- Premisecitation
Low sex hormone levels are associated with inflammation.
“Low sex hormone levels are associated with inflammation (62).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [62] source
Not checked in the free run.
- Interpretationcitation
In severe clinical depression, receptiveness for testosterone effects likely depends on the overall pattern of disturbed neurotransmitters, especially noradrenaline and serotonin, and baseline testosterone concentrations.
“It is likely that, in severe clinical depression, the receptiveness for testosterone effects depends on the overall pattern of disturbed neurotransmitters, especially noradrenaline and serotonin, and also baseline testosterone concentrations (78).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [78] source
Not checked in the free run.
- Premisecitation
Testosterone inhibits the expression of the activity of lipoprotein lipase, the main enzymatic regulator of triglyceride uptake in the fat cell, preferentially in abdominal fat.
“Testosterone inhibits the expression of the activity of lipoprotein lipase, the main enzymatic regulator of triglyceride uptake in the fat cell, preferentially in abdominal fat (28, 29).”
Quote in the paperNot a substantial claim0 of 2 sources checked - Premisecitation
Acute testosterone fall during deprivation therapy is directly related to a worsening in insulin sensitivity.
“but there is evidence that acute testosterone fall during deprivation therapy is directly related to a worsening in insulin sensitivity (53).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [53] source
Not checked in the free run.
- May combine two claims. 59
- Classified as probably not a substantial claim. 8
May combine two claims.
FindingcitationEffects of testosterone on sexual interest appear after 3 weeks and plateau at 6 weeks, with no further increments expected beyond that.
“Effects on sexual interest appear after 3 weeks plateauing at 6 weeks, with no further increments expected beyond.”
- Also stated in: § Effects on libido · plain
“Effects on libido, sexual desire, sexual thoughts and fantasies and satisfaction with sexual life manifest themselves rather rapidly: after 3 weeks (68) or 30 days (14).”
Quote in the paperSubstantial claim0 of 2 sources checked- Also stated in: § Effects on libido · plain
May combine two claims.
FindingcitationEffects of testosterone on quality of life manifest within 3-4 weeks, but maximum benefits take longer.
“Effects on quality of life manifest within 3–4 weeks, but maximum benefits take longer.”
Quote in the paperSubstantial claim0 of 3 sources checkedMay combine two claims.
FindingcitationEffects of testosterone on depressive mood become detectable after 3-6 weeks, with a maximum after 18-30 weeks.
“Effects on depressive mood become detectable after 3–6 weeks with a maximum after 18–30 weeks.”
- Also stated in: § Time-course of effects on psychological variables · hedged
“It is very likely that the positive effects of testosterone on depressive symptoms start as early as after 3–6 weeks, but will most likely take 18–30 weeks to find the patient with a significant improvement.”
Quote in the paperSubstantial claim0 of 2 sources checked- Also stated in: § Time-course of effects on psychological variables · hedged
May combine two claims.
FindingcitationProstate-specific antigen and prostate volume rise marginally and plateau at 12 months during testosterone treatment.
“Prostate-specific antigen and volume rise, marginally, plateauing at 12 months; further increase should be related to aging rather than therapy.”
Quote in the paperSubstantial claim0 of 3 sources checkedMay combine two claims.
FindingcitationEffects of testosterone on erythropoiesis are evident at 3 months and peak at 9-12 months.
“Effects on erythropoiesis are evident at 3 months, peaking at 9–12 months.”
- Also stated in: § Time-course of effects on erythropoiesis · plain
“The effects are apparent after 3 months (14, 35, 40) and a maximum is reached after 9–12 months (35).”
Quote in the paperSubstantial claim0 of 3 sources checked- Also stated in: § Time-course of effects on erythropoiesis · plain
May combine two claims.
FindingcitationEffects of testosterone on lipids appear after 4 weeks and are maximal after 6-12 months.
“Effects on lipids appear after 4 weeks, maximal after 6–12 months.”
Quote in the paperSubstantial claim0 of 3 sources checkedMay combine two claims.
FindingcitationEffects of testosterone on bone are detectable already after 6 months and continue at least for 3 years.
“Effects on bone are detectable already after 6 months while continuing at least for 3 years.”
- Also stated in: § Time-course of effects on bone mineral density · hedged
“From studies analyzing the effects of testosterone administration over as long as 36 months (25, 26) an increase was observed over that time period and it did not become clear whether the maximum effects of testosterone improving bone mineral have been attained after 36 months.”
Quote in the paperSubstantial claim0 of 3 sources checked- Also stated in: § Time-course of effects on bone mineral density · hedged
May combine two claims.
FindingcitationTestosterone treatment decreases trunk fat or waist circumference after 3 months, with continuous decline over 24 months.
“A decrease in trunk fat or waist circumference was noted in a number of studies after 3 months (35, 36) with continuous decline over 24 months (32)”
Quote in the paperSubstantial claim0 of 3 sources checkedMay combine two claims.
FindingcitationIn studies of testosterone administration up to 36 months, bone mineral density increases over that period, and it is unclear whether maximum effects are attained after 36 months.
“From studies analyzing the effects of testosterone administration over as long as 36 months (25, 26) an increase was observed over that time period and it did not become clear whether the maximum effects of testosterone improving bone mineral have been attained after 36 months.”
Quote in the paperSubstantial claim0 of 2 sources checkedMay combine two claims.
FindingcitationUpon testosterone administration, fat mass decreases and lean body mass increases, with total body weight often but not always showing no major changes.
“Upon testosterone administration there is a decrease in fat mass and an increase in lean body mass and the net result is often, but not always, that total body weight does not show major changes.”
Quote in the paperSubstantial claim0 of 3 sources checkedMay combine two claims.
FindingcitationEffects of testosterone on muscle strength are demonstrable after 12-20 weeks, and maximum effects are attained after 6 or 12 months depending on the achieved testosterone levels.
“It can be concluded that the effects of testosterone on muscle strength are demonstrable after 12–20 weeks and that depending on the achieved testosterone levels, the maximum effects are attained after 6 or 12 months.”
Quote in the paperSubstantial claim0 of 3 sources checkedMay combine two claims.
FindingcitationSerum triglycerides decrease after 4 weeks and after 3 months of testosterone treatment, with further decrease over 9 or 12 months.
“The decrease in serum triglycerides follows a similar pattern: after 4 weeks (38), after 3 months (35), and with further decrease over 9 months (41) or 12 months (43).”
Quote in the paperSubstantial claim0 of 3 sources checkedMay combine two claims.
FindingcitationLow-density lipoprotein cholesterol decreases after 3 months, after 40-44 weeks, or after 12 months of testosterone treatment, with a maximum observed after 24 months.
“The decrease in low-density lipoprotein cholesterol seems somewhat slower: after 3 months (35), after 40–44 weeks, (44) or after 12 months (42) with a maximum observed after 24 months (32).”
Quote in the paperSubstantial claim0 of 3 sources checkedMay combine two claims.
FindingcitationSerum total cholesterol decreases as quickly as after 4 weeks of testosterone treatment, but most studies report a decrease after 3 months.
“Decreases in serum total cholesterol have been noted as quick as after 4 weeks (38, 39) but most studies have reported a decrease after 3 months (35, 36).”
Quote in the paperSubstantial claim0 of 3 sources checkedMay combine two claims.
FindingcitationBody mass index declines after 6 months of testosterone treatment, with further improvement during an observation period of 2 years.
“Body mass index as a widely used measure of body composition declined after 6 months with further improvement during an observation period of 2 years (32).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [32] source
Not checked in the free run.
May combine two claims.
FindingcitationTestosterone treatment decreases waist hip ratio after 3 months or after 6 months and 30 weeks.
“and a decrease in the waist hip ratio after 3 months (31, 36) or after 6 months and 30 weeks respectively (17).”
Quote in the paperSubstantial claim0 of 3 sources checkedMay combine two claims.
FindingcitationHigh-density lipoprotein cholesterol increases after 3 months, increasing further during 12 months, after 6 months, or close to 1 year, with continuous increase over 24 months.
“An increase was found to occur after 3 months increasing further during 12 months (43), after 6 months, (35) or close to 1 year (44). Continuous increase was observed over 24 months (32).”
Quote in the paperSubstantial claim0 of 3 sources checkedMay combine two claims.
FindingcitationIn men with baseline glucose >110 ng/ml (6.6 mmol/l), serum glucose is reduced after 24 weeks of testosterone treatment, but not significantly in men with baseline glucose <110 ng/ml.
“In a recent study, this was observed after 24 weeks only in men with baseline glucose >110 ng/ml (6.6 mmol/l) but not significantly in men whose baseline glucose levels were <110 ng/ml (6.6 mmol/l) (40).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [40] source
Not checked in the free run.
May combine two claims.
FindingcitationSerum proinsulin and insulin decrease after 3 or 6 months of testosterone treatment, and HOMA-IR decreases after 3 or 6 months.
“A decrease in serum proinsulin and insulin was noted after 3 months (43) or 6 months (45), and a decrease in homeostasis model assessment index of insulin resistance (HOMA-IR) after 3 months (36) or 6 months (45–47).”
Quote in the paperSubstantial claim0 of 3 sources checkedMay combine two claims.
FindingcitationHbA1c declines after 3 months of testosterone treatment, with further decrease after 12 months.
“A decline in HbA1c was observed after 3 months (31, 36, 43) with further decrease after 12 months (43).”
Quote in the paperSubstantial claim0 of 3 sources checkedMay combine two claims.
FindingcitationThe interplay between insulin sensitivity, triglyceride levels, and androgens occurs within a week and is not facilitated by changes in body composition alone.
“Recently, it has been demonstrated that the interplay between insulin sensitivity, triglyceride levels, and androgens is practically immediate, as it occurs within a week, and is not facilitated by changes in body composition alone.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [50] source
Not checked in the free run.
May combine two claims.
FindingcitationArterial stiffness measured as pulse wave velocity decreases after 48 h, and large artery compliance improves after 3 months of testosterone treatment.
“A decrease in arterial stiffness measured as pulse wave velocity was measurable after 48 h (58) and in large artery compliance after 3 months (58).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [58] source
Not checked in the free run.
May combine two claims.
FindingcitationIn men with chronic heart failure, exercise capacity increases after 12 weeks of testosterone treatment, while cardiac index increases after 180 min.
“Exercise capacity in men with chronic heart failure increased after 12 weeks (60), whereas the cardiac index (cardiac output related to body surface) had already increased after 180 min.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [60] source
Not checked in the free run.
May combine two claims.
FindingcitationTestosterone administration decreases C-reactive protein after 3 weeks and after 3 months.
“A decrease in C-reactive protein (CRP) was observed after 3 weeks (63) and in other studies after 3 months (32, 43).”
Quote in the paperSubstantial claim0 of 3 sources checkedMay combine two claims.
FindingcitationTestosterone administration decreases IL6 after 3 weeks and after 16 weeks.
“Already after 3 weeks of testosterone administration, a decline was noted in IL6 (63) and in another study after 16 weeks (64).”
Quote in the paperSubstantial claim0 of 2 sources checkedMay combine two claims.
FindingcitationDiastolic blood pressure declines after 3-9 months of testosterone treatment, and in some studies systolic blood pressure also declines.
“In some studies a decline in diastolic blood pressure has been observed, after 3–9 months (22, 35, 41, 44) and in some studies in systolic blood pressure also (35, 44).”
Quote in the paperSubstantial claim0 of 3 sources checkedMay combine two claims.
FindingcitationAsymmetric dimethylarginine declines upon testosterone administration after 10 days or after 4 weeks.
“Asymmetric dimethylarginine is an endogenous NO synthase inhibitor and appears to decline upon testosterone administration after 10 days (66) or after 4 weeks (67).”
Quote in the paperSubstantial claim0 of 2 sources checkedMay combine two claims.
FindingcitationThe percentage of full erections, sexual performance, and satisfaction with erections increase after 30 days of testosterone treatment.
“An increase in percentage of full erections and sexual performance and satisfaction with erections was noticed after 30 days (14, 69)”
Quote in the paperSubstantial claim0 of 2 sources checkedMay combine two claims.
FindingcitationEjaculations increase after 2 weeks and sexual activity after 3 weeks of testosterone treatment.
“an increase of ejaculations and sexual activity after 2 weeks (70) and 3 weeks respectively (68).”
Quote in the paperSubstantial claim0 of 2 sources checkedMay combine two claims.
FindingcitationIncreases in IIEF erectile function occur after 3 months, while increases in IIEF sexual desire, intercourse satisfaction, and overall satisfaction appear after 6 weeks.
“Increases in the IIEF erectile function have been noted after 3 months (35, 40) but increases in IIEF sexual desire, intercourse satisfaction, and overall satisfaction appear already after 6 weeks (40).”
Quote in the paperSubstantial claim0 of 2 sources checkedMay combine two claims.
FindingcitationMaximal effects of testosterone on erection and ejaculation are usually achieved after 3-6 months but may take up to 1 year in individual cases.
“Maximal effects are usually achieved after 3–6 months (72) but may take even up to 1 year in individual cases (71).”
Quote in the paperSubstantial claim0 of 2 sources checkedMay combine two claims.
FindingcitationIncrease in motivation occurs after 30 days of testosterone treatment and is maintained thereafter.
“There was also an increase in motivation after 30 days which was maintained thereafter (14).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [14] source
Not checked in the free run.
May combine two claims.
FindingcitationIncrease in good mood and decrease in bad mood occur after 3 weeks or 30 days of testosterone treatment.
“Increase in good mood and a decrease in bad mood were noted after 3 weeks (68) or after 30 days (14).”
Quote in the paperSubstantial claim0 of 2 sources checkedMay combine two claims.
FindingcitationImprovements on AMS scores are noted after 1 month, 6 weeks to 3 months, or after 9 months, continuing over a total of 18 months.
“Improvements on scores on the AMS have been noted after 1 month (38), 6 weeks (40) to 3 months on treatment with parenteral testosterone undecanoate (35) or after 9 months on testosterone gel (74) continuing over a total of 18 months (74).”
Quote in the paperSubstantial claim0 of 3 sources checkedMay combine two claims.
FindingcitationIn severely depressed men, effects of testosterone replacement therapy by gel versus placebo are observed within 6 weeks, but the effect is not consistent within the whole group.
“In a larger set of severely depressed men (n=2×50), effects of testosterone replacement therapy (TRT) by gel versus placebo were observed within 6 weeks. The effect was not consistent within the whole group of patients.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [78] source
Not checked in the free run.
May combine two claims.
FindingcitationIncrease in sociability, decrease in anxiety, increase in concentration, and increase in self-confidence are apparent after 3 weeks of testosterone treatment.
“A number of psychological variables (increase in sociability, decrease in anxiety, increase in concentration, and self-confidence) were apparent after 3 weeks (68).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [68] source
Not checked in the free run.
May combine two claims.
FindingcitationA rise in prostate-specific antigen levels is noticed after 6 months of testosterone treatment, with no significant further increase over the following 24 months.
“A rise in PSA levels was noticed after 6 months, whereafter over the following 24 months there was no significant further increase (85).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [85] source
Not checked in the free run.
May combine two claims.
FindingcitationA rise in prostate-specific antigen levels is found after 3 months in some studies and only after 12 months in others.
“Other studies have found a rise of PSA levels after 3 months (40), some only after 12 months (43).”
Quote in the paperNot a substantial claim0 of 2 sources checkedMay combine two claims.
FindingcitationAging itself is a factor in the rise of prostate volume and prostate-specific antigen, and there is no endpoint in the effects of testosterone on the prostate.
“Upon judging the time-course of effects of testosterone on the prostate, it is of note that aging itself is a factor in the rise of both prostate volume and PSA (84), and there is no endpoint in the effects of testosterone on the prostate.”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [84] source
Not checked in the free run.
May combine two claims.
FindingcitationPositive effects of testosterone on depressive symptoms start as early as after 3-6 weeks, but most likely take 18-30 weeks to find a patient with significant improvement.
“It is very likely that the positive effects of testosterone on depressive symptoms start as early as after 3–6 weeks, but will most likely take 18–30 weeks to find the patient with a significant improvement.”
Quote in the paperSubstantial claim0 of 2 sources checkedMay combine two claims.
FindingcitationIn hypogonadal men receiving testosterone plus an aromatase inhibitor, spatial working memory improves within 3 weeks and improves further until week six.
“These patients exhibited a markedly improved spatial working memory within 3 weeks, improving further until week six (81).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [81] source
Not checked in the free run.
May combine two claims.
FindingreasoningEffects of testosterone on libido and other psychological variables and effects on vasculature occur rather rapidly.
“Effects on libido and other psychological variables and effects on vasculature occur rather rapidly.”
Quote in the paperSubstantial claimMay combine two claims.
FindingcitationTestosterone treatment reduces waist circumference, which appears to be a valid parameter of the degree of visceral obesity.
“Several studies have indeed confirmed that testosterone treatment reduces waist circumference which, in its simplicity, appears to be a valid parameter of the degree of visceral obesity (91).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [91] source
Not checked in the free run.
May combine two claims.
Findingown dataIn the authors' own studies, signs and symptoms of the metabolic syndrome improved substantially following administration of long-acting testosterone undecanoate, and improvements in glycemic control and lipids parallel improvements in body composition.
“In our own studies, signs and symptoms of the metabolic syndrome improved substantially following administration of long-acting testosterone undecanoate (32, 35, 92) and improvements in glycemic control and lipids parallel improvements in body composition.”
Quote in the paperNot a substantial claim0 of 3 sources checkedMay combine two claims.
FindingcitationProstate volume increases after 3 months and after 12 months of testosterone treatment.
“An increase in prostate volume was noted after 3 months (86) and after 12 months (44).”
Quote in the paperSubstantial claim0 of 2 sources checkedMay combine two claims.
FindingcitationIn a study of 123 subjects over 42 months of testosterone gel application, serum prostate-specific antigen significantly increases over the first 6 months and then shows no further significant increases with continued testosterone treatment.
“In a study of 123 subjects over 42 months of testosterone gel application, there was significant increase in serum PSA over the first 6 months and then no further significant increases with continued testosterone treatment was found (87).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [87] source
Not checked in the free run.
May combine two claims.
PremisecitationUpon testosterone administration, there is a positive correlation between blood testosterone concentrations and leg press strength, thigh and quadriceps muscle volume, and levels of hemoglobin and IGF1.
“In a series of studies, Bhasin et al. (8) have demonstrated that upon testosterone administration, there is a positive correlation between blood testosterone concentrations and leg press strength, thigh, and quadriceps muscle volume, and, further, levels of hemoglobin and IGF1.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [8] source
Not checked in the free run.
May combine two claims.
PremisecitationA 12-week long-acting testosterone administration increases quadriceps isometric strength, maximal voluntary contraction, and isokinetic strength.
“A study investigating the effect of a 12-week long-acting testosterone administration on maximal exercise capacity and muscle strength found an increase in quadriceps isometric strength, maximal voluntary contraction, and isokinetic strength (peak torque) (12).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [12] source
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationThe anabolic response to testosterone can largely be predicted by the dose administered.
“In a later study, the same group of authors concluded that the anabolic response to testosterone can largely be predicted by the dose administered (9).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [9] source
Not checked in the free run.
May combine two claims.
PremisecitationCombining testosterone with GH increases total lean body mass and appendicular lean tissue, and composite maximum voluntary strength of upper and lower body muscles increases after 16 weeks.
“In a study that combined testosterone with GH, total lean body mass increased, as did appendicular lean tissue. Composite maximum voluntary strength of upper and lower body muscles had increased after 16 weeks (11).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [11] source
Not checked in the free run.
May combine two claims.
PremisecitationTestosterone improves bone mineral density at the lumbar spine compared with placebo, but at the femoral neck improvements are less certain.
“Testosterone improves bone mineral density at the lumbar spine compared with placebo, but at the femoral neck improvements are less certain (19).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [19] source
Not checked in the free run.
May combine two claims.
PremisecitationIn 180 days of treatment with a 1% testosterone gel preparation (50 or 100 mg/day), mean leg press muscle strength increases by 90 days and does not improve further at 180 days.
“In a study of 180 days of treatment with a 1% testosterone gel preparation (50 or 100 mg/day, contained in 5 or 10 g gel), mean muscle strength in the leg press exercise increased by 90 days and had not improved further at 180 days (14).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [14] source
Not checked in the free run.
May combine two claims.
PremisecitationTestosterone enanthate 200 mg/2 weeks produces major effects over the first 12 months of administration, with minor increases thereafter.
“A study administering testosterone enanthate, 200 mg/2 weeks observed major effects to occur over the first 12 months of testosterone administration, thereafter minor increases could be observed (17).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [17] source
Not checked in the free run.
May combine two claims.
PremisecitationTestosterone treatment for 6 months increases lean body mass and improves lower limb muscle strength.
“A study similar in design found an increase in lean body mass and an improvement of lower limb muscle strength after 6 months (15).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [15] source
Not checked in the free run.
May combine two claims.
InterpretationcitationThe metabolic observations of testosterone are most likely attributed to testosterone-induced changes in lipid metabolism and/or altered postreceptor insulin signaling in muscle.
“Such observations are most likely attributed to testosterone-induced changes in lipid metabolism and/or altered postreceptor insulin signaling in muscle (54) and also improved insulin sensitivity enhancing muscle lipid uptake (55).”
Quote in the paperSubstantial claim0 of 2 sources checkedMay combine two claims.
InterpretationreasoningEffects of testosterone on muscle and bone involve protein synthesis and are a result of genomic actions of testosterone and therefore rather slow.
“The effects of testosterone on muscle and bone involve protein synthesis and are a result of genomic actions of testosterone and, therefore, rather slow.”
Quote in the paperSubstantial claimMay combine two claims.
InterpretationcitationEffects of testosterone on erection occur rather rapidly and may be partially explained by non-genomic effects on vascular penile erectile tissue.
“Also effects on erection occur rather rapidly and may be partially explained by non-genomic effects on vascular penile erectile tissue (89).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [89] source
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing), S4 (based).
Premisenone givenEarlier studies have shown that there are thresholds for the various actions of testosterone, such that signs and symptoms of testosterone deficiency appear at different threshold values of circulating testosterone.
“Earlier studies have shown that there are thresholds for the various actions testosterone: in other words signs and symptoms of testosterone deficiency appear at different threshold values of circulating testosterone.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationThere is a degree of consensus that elderly men with serum testosterone clearly below the reference ranges and persistent clear clinical signs of hypogonadism may justifiably be treated.
“There is a degree of consensus that elderly men with serum testosterone clearly below the reference ranges and persistent clear clinical signs of hypogonadism may justifiably be treated (98, 99)”
Quote in the paperNot a substantial claim0 of 2 sources checkedClassified as probably not a substantial claim.
PremisecitationA verdict on treating elderly men with lower than normal testosterone levels can only be reached with large-scale studies including 5000 men over 5 years.
“a verdict can only be reached with large-scale studies including 5000 men over 5 years (95)”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [95] source
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
PremisecitationSmall-scale studies show benefits and acceptable risks of treating elderly men with lower than normal testosterone levels.
“Though small-scale studies show benefits and acceptable risks of treating elderly men with lower than normal testosterone levels (46, 97)”
Quote in the paperNot a substantial claim0 of 2 sources checkedProbably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
PremisecitationSome biological functions, such as erectile function, are composite in nature, and in addition to testosterone, endothelial function and psychological factors are equally relevant.
“Some biological functions, like erectile functions are composite in nature, and next to testosterone, endothelial function and psychological factors are equally relevant (2).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [2] source
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
PremisecitationIt is still hotly debated whether late-onset hypogonadism is a true form of hypogonadism or a decline of serum testosterone associated with the progressive accumulation of health problems with aging, rather independently of the process of aging itself.
“It is still hotly debated whether this is a true form of hypogonadism, or a decline of serum testosterone associated with the progressive accumulation of health problems with aging (95, 96), but rather independently of the process of aging itself.”
Quote in the paperNot a substantial claim0 of 2 sources checkedClassified as probably not a substantial claim.
Study design and conductnone givenIn the present analysis, an attempt was made to select studies of testosterone treatment that provided adequate doses/delivery of testosterone.
“Finally, in the present analysis it was attempted to select those studies of testosterone treatment that provided adequate doses/delivery of testosterone.”
Quote in the paperSubstantial claim- Rests on an assumption: Sub-optimal therapeutic regimens or inappropriate patient selection (eugonadal or men with biochemical but not clinical hypogonadism) may show different time-course of effects.
The paper relies on this without support.
The available controlled studies, despite not being specifically designed to assess onset or time-dependency, allow a reasonable estimation of the time-course of testosterone effects.
“Nearly all of these studies were not specifically designed to address the onset or time-dependency of effects of testosterone, nevertheless a number of controlled studies with different design and scheduled follow-up, allow a reasonable estimation.”
The paper relies on this without support.
The time-course of the diverse actions of testosterone can be compiled across studies of testosterone administration to hypogonadal men and studies on androgen deprivation.
“Data to compile a time-course for the diverse actions of testosterone are not easily available. They originate from studies analyzing the effects of testosterone administration to hypogonadal men or, alternatively, from studies on androgen deprivation. The main source of information will be the former category.”
The paper relies on this without support.
Deprivation of testosterone and its time-dependent effects might be totally different from the onset of testosterone action in testosterone treatment, even in the same parameter.
“However, deprivation of testosterone and the time-dependent effects thereof might be totally different from the onset of testosterone action in testosterone treatment, even in the same parameter.”
The paper relies on this without support.
Sub-optimal therapeutic regimens or inappropriate patient selection (eugonadal or men with biochemical but not clinical hypogonadism) may show different time-course of effects.
“It is obvious that sub-optimal therapeutic regimens or, alternatively, inappropriate patient selection (eugonadal or men with biochemical but not clinical hypogonadism) may show different time-course of effects.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Obesity-related male hypogonadism is considered a form of hypogonadotropic hypogonadism.
“Based on these and other studies (53,54), obesity-related male hypogonadism is now considered as a form of hypogonadotropic hypogonadism (see for a review, references (55,56)).”
From Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis (2013) · cites this paper as [56]
The Discussion addresses testosterone treatment, visceral obesity and metabolic syndrome, but does not classify obesity-related male hypogonadism as hypogonadotropic. Searches for that classification and for “hypogonadotropic” found the term only in titles in the References, not a passage making the claimed connection; page numbers were unavailable in our copy. (LLM, conf=0.74)
Experimental — accuracy not yet measuredHigh BMI seems to repress serum testosterone mainly via central inhibitory effects on gonadotropin secretion.
“Thus high BMI seems to repress serum T mainly via central inhibitory effects on gonadotropin secretion [38, 41].”
From Causal relationship between obesity and serum testosterone status in men: A bi-directional mendelian randomization analysis (2017) · cites this paper as [41]
Cites
Bhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2354 · Cited by 1,954 · see citing works
Adverse Events Associated with Testosterone Administration
Basaria, S., Coviello, A. D., Travison, T. G., Storer, T. W., Farwell, W. R., Jette, A. M., Eder, R., Tennstedt, S., Ulloor, J., Zhang, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000485 · Cited by 1,494 · see citing works
Testosterone dose-response relationships in healthy young men
Bhasin, S., Woodhouse, L., Casaburi, R., Singh, A. B., Bhasin, D., Berman, N., Chen, X., Yarasheski, K. E., Magliano, L., Dzekov, C., et al. (2001) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2001.281.6.e1172 · Cited by 967 · see citing works
Investigation, treatment and monitoring of late-onset hypogonadism in males
Wang, C., Nieschlag, E., Swerdloff, R., Behre, H. M., Hellstrom, W. J., Gooren, L. J., Kaufman, J. M., Legros, J.-J., Lunenfeld, B., Morales, A., et al. (2008) · European Journal of Endocrinology · doi:10.1530/eje-08-0601 · Cited by 867 · see citing works
Self-citationKapoor, D., Goodwin, E., Channer, K. S., & Jones, T. H. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02166 · Cited by 791 · see citing works
Effects of testosterone supplementation in the aging male
Tenover, J. S. (1992) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.75.4.1092 · Cited by 768 · see citing works
Malkin, C. J., Pugh, P. J., Jones, R. D., Kapoor, D., Channer, K. S., & Jones, T. H. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031069 · Cited by 731 · see citing works
Effects of testosterone supplementation in the aging male.
Tenover, J. S. (1992) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.75.4.1400877 · Cited by 702 · see citing works
Isidori, A. M., Giannetta, E., Greco, E. A., Gianfrilli, D., Bonifacio, V., Isidori, A., Lenzi, A., & Fabbri, A. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2005.02339.x · Cited by 695 · see citing works
Self-citationWang, C., Cunningham, G., Dobs, A., Iranmanesh, A., Matsumoto, A. M., Snyder, P. J., Weber, T., Berman, N., Hull, L., & Swerdloff, R. S. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032006 · Cited by 656 · see citing works
Srinivas-Shankar, U., Roberts, S. A., Connolly, M. J., O'Connell, M. D. L., Adams, J. E., Oldham, J. A., & Wu, F. C. W. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1251 · Cited by 629 · see citing works
Effects of Testosterone Replacement in Hypogonadal Men1
Snyder, P. J., Peachey, H., Berlin, J. A., Hannoush, P., Haddad, G., Dlewati, A., Santanna, J., Loh, L., Lenrow, D. A., Holmes, J. H., et al. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.8.6731 · Cited by 608 · see citing works
English, K. M., Steeds, R. P., Jones, T. H., Diver, M. J., & Channer, K. S. (2000) · Circulation · doi:10.1161/01.cir.102.16.1906 · Cited by 582 · see citing works
Page, S. T., Amory, J. K., Bowman, F. D., Anawalt, B. D., Matsumoto, A. M., Bremner, W. J., & Tenover, J. L. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1933 · Cited by 566 · see citing works
Singh, R., Artaza, J. N., Taylor, W. E., Gonzalez-Cadavid, N. F., & Bhasin, S. (2003) · Endocrinology · doi:10.1210/en.2003-0741 · Cited by 555 · see citing works
Association of Specific Symptoms and Metabolic Risks with Serum Testosterone in Older Men
Zitzmann, M., Faber, S., & Nieschlag, E. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0401 · Cited by 552 · see citing works
Self-citationEffect of Testosterone Treatment on Body Composition and Muscle Strength in Men Over 65 Years of Age
Snyder, P. J. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.8.2647 · Cited by 531 · see citing works
Pitteloud, N., Hardin, M., Dwyer, A. A., Valassi, E., Yialamas, M., Elahi, D., & Hayes, F. J. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2190 · Cited by 525 · see citing works
Emmelot-Vonk, M. H., Verhaar, H. J. J., Nakhai Pour, H. R., Aleman, A., Lock, T. M. T. W., Bosch, J. L. H. R., Grobbee, D. E., & van der Schouw, Y. T. (2008) · JAMA · doi:10.1001/jama.2007.51 · Cited by 518 · see citing works
Non-genomic actions of androgens
Foradori, C. D., Weiser, M. J., & Handa, R. J. (2008) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2007.10.005 · Cited by 493 · see citing works
Amory, J. K., Watts, N. B., Easley, K. A., Sutton, P. R., Anawalt, B. D., Matsumoto, A. M., Bremner, W. J., & Tenover, J. L. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031110 · Cited by 475 · see citing works
Relationship Between Testosterone Levels, Insulin Sensitivity, and Mitochondrial Function in Men
Pitteloud, N., Mootha, V. K., Dwyer, A. A., Hardin, M., Lee, H., Eriksson, K.-F., Tripathy, D., Yialamas, M., Groop, L., Elahi, D., et al. (2005) · Diabetes Care · doi:10.2337/diacare.28.7.1636 · Cited by 472 · see citing works
Effects of Testosterone Replacement in Hypogonadal Men
Snyder, P. J. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.8.2670 · Cited by 464 · see citing works
Effect of Testosterone Treatment on Bone Mineral Density in Men Over 65 Years of Age
Snyder, P. J. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.6.1966 · Cited by 460 · see citing works
Caminiti, G., Volterrani, M., Iellamo, F., Marazzi, G., Massaro, R., Miceli, M., Mammi, C., Piepoli, M., Fini, M., & Rosano, G. M. C. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.04.078 · Cited by 444 · see citing works
Effects of graded doses of testosterone on erythropoiesis in healthy young and older men
Coviello, A. D., Kaplan, B., Lakshman, K. M., Chen, T., Singh, A. B., & Bhasin, S. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1692 · Cited by 404 · see citing works
Dose-Response Effect of Elevated Plasma Free Fatty Acid on Insulin Signaling
Belfort, R., Mandarino, L., Kashyap, S., Wirfel, K., Pratipanawatr, T., Berria, R., DeFronzo, R. A., & Cusi, K. (2005) · Diabetes · doi:10.2337/diabetes.54.6.1640 · Cited by 404 · see citing works
The endocrinology of sexual arousal
Bancroft, J. (2005) · Journal of Endocrinology · doi:10.1677/joe.1.06233 · Cited by 398 · see citing works
Levine, G. N., D'Amico, A. V., Berger, P., Clark, P. E., Eckel, R. H., Keating, N. L., Milani, R. V., Sagalowsky, A. I., Smith, M. R., & Zakai, N. (2010) · Circulation · doi:10.1161/circulationaha.109.192695 · Cited by 383 · see citing works
Boyanov, M. A., Boneva, Z., & Christov, V. G. (2003) · The Aging Male · doi:10.1080/tam.6.1.1.7 · Cited by 381 · see citing works
Dobs, A. S. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.10.3469 · Cited by 381 · see citing works
Singh, R., Artaza, J. N., Taylor, W. E., Braga, M., Yuan, X., Gonzalez-Cadavid, N. F., & Bhasin, S. (2006) · Endocrinology · doi:10.1210/en.2004-1649 · Cited by 369 · see citing works
Wang, C. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.8.2839 · Cited by 359 · see citing works
Testosterone deficiency, insulin resistance and the metabolic syndrome
Zitzmann, M. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.212 · Cited by 353 · see citing works
Self-citationMetabolic Complications of Androgen Deprivation Therapy for Prostate Cancer
Saylor, P. J., & Smith, M. R. (2009) · The Journal of Urology · doi:10.1016/j.juro.2009.01.047 · Cited by 349 · see citing works
Heufelder, A. E., Saad, F., Bunck, M. C., & Gooren, L. (2009) · Journal of Andrology · doi:10.2164/jandrol.108.007005 · Cited by 349 · see citing works
Self-citationAndrogen Treatment of Abdominally Obese Men
Mårin, P., Holmtäng, S., Gustafsson, C., Jönsson, ‡., Kvist, ‡., Elander, A., Eldh, J., Sjöström, L., Holm, G., & Björntorp, P. (1993) · Obesity Research · doi:10.1002/j.1550-8528.1993.tb00618.x · Cited by 345 · see citing works
Aversa, A., Isidori, A. M., Spera, G., Lenzi, A., & Fabbri, A. (2003) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2003.01764.x · Cited by 343 · see citing works
Self-citationPope, H. G., Cohane, G. H., Kanayama, G., Siegel, A. J., & Hudson, J. I. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.1.105 · Cited by 341 · see citing works
Behre, H. M., Bohmeyer, J., & Nieschlag, E. (1994) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1994.tb03929.x · Cited by 335 · see citing works
Tracz, M. J., Sideras, K., Boloña, E. R., Haddad, R. M., Kennedy, C. C., Uraga, M. V., Caples, S. M., Erwin, P. J., & Montori, V. M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0036 · Cited by 275 · see citing works
Aversa, A., Bruzziches, R., Francomano, D., Rosano, G., Isidori, A. M., Lenzi, A., & Spera, G. (2010) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2010.01931.x · Cited by 265 · see citing works
Self-citationMalkin, C. J., Pugh, P. J., Morris, P. D., Kerry, K. E., Jones, R. D., Jones, T. H., & Channer, K. S. (2004) · Heart · doi:10.1136/hrt.2003.021121 · Cited by 250 · see citing works
The role of aromatization in testosterone supplementation: Effects on cognition in older men
Cherrier, M. M., Matsumoto, A. M., Amory, J. K., Ahmed, S., Bremner, W., Peskind, E. R., Raskind, M. A., Johnson, M., & Craft, S. (2005) · Neurology · doi:10.1212/01.wnl.0000149639.25136.ca · Cited by 226 · see citing works
Testosterone treatment for men with chronic heart failure
Pugh, P. J., Jones, R. D., West, J. N., Jones, T. H., & Channer, K. S. (2004) · Heart · doi:10.1136/hrt.2003.014639 · Cited by 221 · see citing works
Yialamas, M. A., Dwyer, A. A., Hanley, E., Lee, H., Pitteloud, N., & Hayes, F. J. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0454 · Cited by 220 · see citing works
Zitzmann, M., & Nieschlag, E. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0620 · Cited by 216 · see citing works
Self-citationUkropcova, B., McNeil, M., Sereda, O., de Jonge, L., Xie, H., Bray, G. A., & Smith, S. R. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24332 · Cited by 213 · see citing works
Bosy‐Westphal, A., Booke, C.-A., Blöcker, T., Kossel, E., Goele, K., Later, W., Hitze, B., Heller, M., Glüer, C., & Müller, M. J. (2010) · Journal of Nutrition · doi:10.3945/jn.109.118737 · Cited by 201 · see citing works
Maggio, M., Basaria, S., Ble, A., Lauretani, F., Bandinelli, S., Ceda, G. P., Valenti, G., Ling, S. M., & Ferrucci, L. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1097 · Cited by 200 · see citing works
Testosterone and Growth Hormone Improve Body Composition and Muscle Performance in Older Men
Sattler, F. R., Castaneda-Sceppa, C., Binder, E. F., Schroeder, E. T., Wang, Y., Bhasin, S., Kawakubo, M., Stewart, Y., Yarasheski, K. E., Ulloor, J., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2338 · Cited by 194 · see citing works
Levine, G. N., D'Amico, A. V., Berger, P., Clark, P. E., Eckel, R. H., Keating, N. L., Milani, R. V., Sagalowsky, A. I., Smith, M. R., Zakai, N., et al. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20061 · Cited by 188 · see citing works
Allan, C. A., & McLachlan, R. I. (2010) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0b013e3283398ee2 · Cited by 168 · see citing works
Effect of testosterone replacement therapy on lipids and lipoproteins in hypogonadal and elderly men
Zgliczynski, S., Ossowski, M., Slowinska-Srzednicka, J., Brzezinska, A., Zgliczynski, W., Soszynski, P., Chotkowska, E., Srzednicki, M., & Sadowski, Z. (1996) · Atherosclerosis · doi:10.1016/0021-9150(95)05673-4 · Cited by 167 · see citing works
O’Connor, D. B., Archer, J., & Wu, F. C. W. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031354 · Cited by 149 · see citing works
Storer, T. W., Woodhouse, L., Magliano, L., Singh, A. B., Dzekov, C., Dzekov, J., & Bhasin, S. (2008) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2008.01927.x · Cited by 145 · see citing works
Giltay, E. J., Tishova, Y. A., Mskhalaya, G. J., Gooren, L. J. G., Saad, F., & Kalinchenko, S. Y. (2010) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2010.01859.x · Cited by 140 · see citing works
Self-citationNieschlag, E., Büchter, D., Von Eckardstein, S., Abshagen, K., Simoni, M., & Behre, H. M. (1999) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1999.00881.x · Cited by 140 · see citing works
Song, D. H., Getty–Kaushik, L., Tseng, E., Simon, J., Corkey, B. E., & Wolfe, M. M. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.09.005 · Cited by 137 · see citing works
The Aging Males' Symptoms (AMS) scale: review of its methodological characteristics.
Daig, I., Heinemann, L. A. J., Kim, S., Leungwattanakij, S., Badia, X. C., Myon, E., Moore, C., Saad, F., Potthoff, P., & Thai, D. M. (2003) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-1-77 · Cited by 137 · see citing works
Self-citationTestosterone treatment comes of age: new options for hypogonadal men
Nieschlag, E. (2006) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2006.02618.x · Cited by 137 · see citing works
Saad, F., Gooren, L. J., Haider, A., & Yassin, A. (2008) · Journal of Andrology · doi:10.2164/jandrol.107.002774 · Cited by 132 · see citing works
Self-citationWayne Meikle, A., Arver, S., Dobs, A. S., Adolfsson, J., Sanders, S. W., Middleton, R. G., Stephenson, R. A., Hoover, D. R., Rajaram, L., & Mazer, N. A. (1997) · Urology · doi:10.1016/s0090-4295(96)00445-1 · Cited by 125 · see citing works
Testosterone Replacement Therapy Restores Normal Ghrelin in Hypogonadal Men
Pagotto, U., Gambineri, A., Pelusi, C., Genghini, S., Cacciari, M., Otto, B., Castañeda, T., Tschöp, M., & Pasquali, R. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030554 · Cited by 120 · see citing works
Anderson, F. H., Francis, R. M., & Faulkner, K. (1996) · Bone · doi:10.1016/8756-3282(95)00441-6 · Cited by 119 · see citing works
Why Is Androgen Replacement in Males Controversial?
Cunningham, G. R., & Toma, S. M. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0266 · Cited by 111 · see citing works
Kang, S.-M., Jang, Y., Kim, J. I.-Y., Chung, N., Cho, S.-Y., Chae, J. S., & Lee, J.-H. O. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02202-6 · Cited by 105 · see citing works
Improvement of Sexual Function in Men with Late-Onset Hypogonadism Treated with Testosterone Only
Yassin, A. A., & Saad, F. (2007) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2007.00442.x · Cited by 101 · see citing works
Self-citationYassin, A. A., Saad, F., & Traish, A. (2006) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2006.00267.x · Cited by 96 · see citing works
Self-citationPope, H. G., Amiaz, R., Brennan, B. P., Orr, G., Weiser, M., Kelly, J. F., Kanayama, G., Siegel, A., Hudson, J. I., & Seidman, S. N. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181d207ca · Cited by 90 · see citing works
Saad, F., Gooren, L., Haider, A., & Yassin, A. (2008) · Andrologia · doi:10.1111/j.1439-0272.2008.00807.x · Cited by 89 · see citing works
Self-citationSaad, F., Gooren, L., Haider, A., & Yassin, A. (2007) · Archives of Andrology · doi:10.1080/01485010701730880 · Cited by 87 · see citing works
Self-citationVascular Reactivity in Hypogonadal Men Is Reduced by Androgen Substitution
Zitzmann, M., Brune, M., & Nieschlag, E. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020504 · Cited by 86 · see citing works
Self-citationHaider, A., Gooren, L. J. G., Padungtod, P., & Saad, F. (2009) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0029-1202774 · Cited by 83 · see citing works
Self-citationEffect of testosterone on <i>ex vivo</i> vascular reactivity in man
Malkin, C. J., Jones, R. D., Jones, T. H., & Channer, K. S. (2006) · Clinical Science · doi:10.1042/cs20050354 · Cited by 81 · see citing works
Effect of testosterone replacement therapy on arterial stiffness in older hypogonadal men
Yaron, M., Greenman, Y., Rosenfeld, J. B., Izkhakov, E., Limor, R., Osher, E., Shenkerman, G., Tordjman, K., & Stern, N. (2009) · European Journal of Endocrinology · doi:10.1530/eje-09-0052 · Cited by 78 · see citing works
Agledahl, I., Skjærpe, P. A., Hansen, J., & Svartberg, J. B. (2007) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2007.01.014 · Cited by 77 · see citing works
Testosterone Therapy in Late-Life Major Depression in Males
Perry, P. J., Yates, W. R., Williams, R. D., Andersen, A. E., MacIndoe, J. H., Lund, B. C., & Holman, T. L. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n1202 · Cited by 75 · see citing works
Effect of Testosterone on Insulin Sensitivity in Men with Idiopathic Hypogonadotropic Hypogonadism
Naharcı, M. İ., Pinar, M., Bolu, E., & Olgun, A. (2007) · Endocrine Practice · doi:10.4158/ep.13.6.629 · Cited by 74 · see citing works
Woodhouse, L. J., Reisz-Porszasz, S., Javanbakht, M., Storer, T. W., Lee, M., Zerounian, H., & Bhasin, S. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00536.2002 · Cited by 73 · see citing works
Coward, R. M., Simhan, J., & Carson III, C. C. (2009) · BJU International · doi:10.1111/j.1464-410x.2008.08240.x · Cited by 70 · see citing works
The role of estrogens for male bone health
Ohlsson, C., & Vandenput, L. (2009) · European Journal of Endocrinology · doi:10.1530/eje-09-0118 · Cited by 62 · see citing works
Late-Life Onset Hypogonadism: A Review
Bassil, N., & Morley, J. E. (2010) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2010.02.003 · Cited by 59 · see citing works
Effect of testosterone therapy on lumbar spine and hip mineral density in elderly men
Basurto, L., Zárate, A., Gómez, R. N. M. M., Vargas, C. D. V., Saucedo, R., & Galván, R. E. (2008) · The Aging Male · doi:10.1080/13685530802273715 · Cited by 56 · see citing works
Wang, C. (2002) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.4.1462 · Cited by 54 · see citing works
Zitzmann, M., Weckesser, M., Schober, O., & Nieschlag, E. (2001) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-2001-16351 · Cited by 52 · see citing works
Self-citationZitzmann, M., Erren, M., Kamischke, A., Simoni, M., & Nieschlag, E. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0847 · Cited by 49 · see citing works
Self-citationMoon, D. G., Park, M. G., Lee, S. W., Park, K., Park, J. K., Kim, S. W., Park, N. C., Ahn, T. Y., Paick, J. S., Seo, J. T., et al. (2010) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2010.01765.x · Cited by 46 · see citing works
Glucose-dependent insulinotropic polypeptide (GIP) stimulates transepithelial glucose transport
Singh, S. K., Bartoo, A. C., Krishnan, S., Boylan, M. O., Schwartz, J. H., & Wolfe, M. M. (2008) · Obesity · doi:10.1038/oby.2008.393 · Cited by 40 · see citing works
Rosenstock, J., Fonseca, V. A., Garvey, W. T., Goldberg, R. B., Handelsman, Y., Abby, S. L., Lai, Y.-L., Jin, X., Misir, S., Nagendran, S., et al. (2010) · Endocrine Practice · doi:10.4158/ep10130.or · Cited by 35 · see citing works
Minnemann, T., Schubert, M., Freude, S., Hübler, D., Gouni-Berthold, I., Schumann, C. Y., Christoph, A., Oettel, M., Ernst, M. E., Mellinger, U., et al. (2008) · Journal of Endocrinological Investigation · doi:10.1007/bf03346421 · Cited by 35 · see citing works
Guler, N., Batyraliev, T., Dulger, H., Ozkara, C., Tuncer, M., Aslan, S., Okut, H., & Agirbasli, M. (2006) · International Journal of Cardiology · doi:10.1016/j.ijcard.2005.06.027 · Cited by 33 · see citing works
Lapauw, B., Ouwens, M., ′t Hart, L. M., Wuyts, B., Holst, J. J., T'Sjoen, G., Kaufman, J.-M., & Ruige, J. B. (2010) · Diabetes Care · doi:10.2337/dc10-0515 · Cited by 32 · see citing works
Timetable of effects of testosterone administration to hypogonadal men on variables of sex and mood
Jockenhövel, F., Minnemann, T., Schubert, M., Freude, S., Hübler, D., Schumann, C., Christoph, A., Gooren, L., & Ernst, M. (2009) · The Aging Male · doi:10.3109/13685530903322858 · Cited by 31 · see citing works
Self-citationCakir, E., Ozcan, O., Yaman, H., Akgul, E. O., Bilgi, C., Erbil, M. K., & Yesilova, Z. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2045 · Cited by 28 · see citing works
Non‐genomic effects of androgens on isolated human vascular and nonvascular penile erectile tissue
Waldkirch, E., Ückert, S., Schultheiss, D., Geismar, U., Bruns, C., Scheller, F., Jonas, U., Becker, A. J., Stief, C. G., & Hedlund, P. (2008) · BJU International · doi:10.1111/j.1464-410x.2007.07182.x · Cited by 27 · see citing works
Androgen deficiency and hormone‐replacement therapy
Isidori, A. M., Greco, E. A., & Aversa, A. (2005) · British Journal of Urology · doi:10.1111/j.1464-410x.2005.05603.x · Cited by 21 · see citing works
Self-citationCertainly More Guidelines than Rules
McLachlan, R. I. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0838 · Cited by 18 · see citing works
Leifke, E., Kinzel, M., Tsikas, D., Gooren, L., Frölich, J., & Brabant, G. (2008) · Hormone and Metabolic Research · doi:10.1055/s-2007-1004529 · Cited by 18 · see citing works
Self-citationImpact of Acute Biochemical Castration on Insulin Sensitivity in Healthy Adult Men
Rabiee, A., Dwyer, A. A., Caronia, L. M., Hayes, F. J., Yialamas, M. A., Andersen, D. K., Thomas, B. J., Torriani, M., & Elahi, D. (2010) · Endocrine Research · doi:10.3109/07435801003705601 · Cited by 17 · see citing works
Low Fasting Triglycerides: Hallmark of the Healthy Large Hip?
Ruige, J. B., & Gaal, L. F. V. (2009) · Obesity · doi:10.1038/oby.2009.25 · Cited by 14 · see citing works
Metabolic abnormalities identified by anthropometric measures in elderly men
Esmaillzadeh, A., Mirmiran, P., & Azizi, F. (2006) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/83.1.173 · Cited by 10 · see citing works
Haider, A., Kurtz, W., Giltay, E. J., Gooren, L. J., & Saad, F. (2010) · hmbci · doi:10.1515/hmbci.2010.033 · Cited by 10 · see citing works
Self-citationBrooke, M. H. (2006) · Neurology · doi:10.1212/01.wnl.0000195276.90205.d8 · Cited by 8 · see citing works
Flagged first, then by citations
Research works printed but not linked: 5
- 1996, 18, 171
- 1996, 121, 35
- 2007, ENDOCRINE PRACTICE, 16, 629
- 2007, 133, 1796
- 2002, Clinical Psychology: Science and Practice, 63, 1096
Cited by
Sorted by citations
Yafi, F. A., Jenkins, L., Albersen, M., Corona, G., Isidori, A. M., Goldfarb, S., Maggi, M., Nelson, C. J., Parish, S., Salonia, A., et al. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.3 · Cited by 853 · see citing works
Kelly, D. M., & Jones, T. H. (2015) · Obesity Reviews · doi:10.1111/obr.12282 · Cited by 487 · see citing works
Corona, G., Rastrelli, G., Monami, M., Saad, F., Luconi, M., Lucchese, M., Facchiano, E., Sforza, A., Forti, G., Mannucci, E., et al. (2013) · European Journal of Endocrinology · doi:10.1530/eje-12-0955 · Cited by 414 · see citing works
Self-citationHackett, G., Cole, N., Bhartia, M., Kennedy, D., Raju, J., & Wilkinson, P. (2013) · The Journal of Sexual Medicine · doi:10.1111/jsm.12146 · Cited by 182 · see citing works
Hackett, G., Cole, N., Bhartia, M., Kennedy, D., Raju, J., Wilkinson, P., & the BLAST Study Group (2014) · The Journal of Sexual Medicine · doi:10.1111/jsm.12404 · Cited by 168 · see citing works
Hoyos, C. M., Yee, B. J., Phillips, C. L., Machan, E. A., Grunstein, R. R., & Liu, P. Y. (2012) · European Journal of Endocrinology · doi:10.1530/eje-12-0525 · Cited by 145 · see citing works
Zitzmann, M., Mattern, A., Hanisch, J., Gooren, L., Jones, H., & Maggi, M. (2013) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2012.02853.x · Cited by 122 · see citing works
Self-citationDefreyne, J., Vantomme, B., Van Caenegem, E., Wierckx, K., De Blok, C. J. M., Klaver, M., Nota, N. M., Van Dijk, D., Wiepjes, C. M., Den Heijer, M., et al. (2018) · Andrology · doi:10.1111/andr.12485 · Cited by 114 · see citing works
Aversa, A., Bruzziches, R., Francomano, D., Greco, E. A., Fornari, R., Luigi, L. D., Lenzi, A., & Migliaccio, S. (2012) · The Aging Male · doi:10.3109/13685538.2011.631230 · Cited by 108 · see citing works
Self-citationEriksson, J., Haring, R., Grarup, N., Vandenput, L., Wallaschofski, H., Lorentzen, E., Hansen, T., Mellström, D., Pedersen, O., Nauck, M., et al. (2017) · PLOS ONE · doi:10.1371/journal.pone.0176277 · Cited by 101 · see citing works
Patient satisfaction with testosterone replacement therapies: the reasons behind the choices
Kovac, J. R., Rajanahally, S., Smith, R. P., Coward, R. M., Lamb, D. J., & Lipshultz, L. I. (2014) · The Journal of Sexual Medicine · doi:10.1111/jsm.12369 · Cited by 42 · see citing works
Melehan, K. L., Hoyos, C. M., Yee, B. J., Wong, K. K., Buchanan, P. R., Grunstein, R. R., & Liu, P. Y. (2016) · Andrology · doi:10.1111/andr.12132 · Cited by 26 · see citing works
Very low‐calorie ketogenic diet rapidly augments testosterone levels in non‐diabetic obese subjects
Cignarelli, A., Santi, D., Genchi, V. A., Conte, E., Giordano, F., Di Leo, S., Natalicchio, A., Laviola, L., Giorgino, F., & Perrini, S. (2023) · Andrology · doi:10.1111/andr.13357 · Cited by 19 · see citing works
Certainly More Guidelines than Rules
McLachlan, R. I. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0838 · Cited by 18 · see citing works
Sansone, A., & Romanelli, F. (2021) · Human Aging · doi:10.1016/b978-0-12-822569-1.00007-x · Cited by 5 · see citing works
- Authors
- Saad, F., Aversa, A., Isidori, A. M., Zafalon, L., Zitzmann, M., & Gooren, L.
- Affiliations
- Gulf Medical University (AE)
- Sapienza University of Rome (IT)
- University of Münster (DE)
- Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
- Corresponding author
- Saad, Farid
- Venue
- European Journal of Endocrinology
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-11
- Volume
- 165
- Issue
- 5
- Pages
- 675-685
- ISSN
- 0804-4643 (ISSN-L)
- 1479-683X
- PMC
- PMC3188848
- OpenAlex
- W2123994640
- Semantic Scholar
- d5b89a0b7567a3389c8a0477c9569f998d47f246
- Cited by
- 232
- References
- 104
- Citations by year
- 2026: 11 · 2025: 11 · 2024: 12 · 2023: 14 · 2022: 12 · 2021: 18 · 2020: 17 · 2019: 11 · 2018: 12 · 2017: 15 · 2016: 14 · 2015: 23 · 2014: 23 · 2013: 19 · 2012: 17
- FWCI
- 2.66
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- European Journal of Endocrinology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Keywords
- testosterone replacement therapy, time course of treatment effects, sexual interest, erectile function, quality of life, depressive mood, erythropoiesis, prostate-specific antigen, lipid metabolism, insulin sensitivity, glycemic control, body composition, muscle strength, inflammation, bone metabolism, androgen receptor polymorphism, pharmacodynamics
- MeSH terms
- Animals, Humans, Male, Testosterone, Time Factors, Treatment Outcome, Hormone Replacement Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Claims read by deepseek-v4.1-flash under definition version 3 (extract-v3) on 2026-10-10.
Classified by jev-1.13-20260917 (gold-guideline-v0.2) on 2026-10-10.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review